Target intelligence / Profile preview

V-type proton ATPase subunit d1 (ATP6V0D1)

Target
ATP6V0D1
Molecular classification
Enzyme, Transporter, ATPase
01

Overview

V-type proton ATPase subunit d1 (ATP6V0D1) is a component of vacuolar ATPase (V-ATPase), a multisubunit enzyme complex that physically resides within cellular membranes and orchestrates the acidification of organelles such as lysosomes, endosomes, and secretory vesicles[1][2][3]. This subunit is part of the V0 (membrane-bound) domain of V-ATPase, contributing to the proton translocation mechanism which is coupled to ATP hydrolysis in the V1 (cytosolic) domain[1][3]. Acidification generated by V-ATPase is vital for key cellular processes including proteolytic activation, protein sorting, synaptic function, and autophagy, as well as regulating iron metabolism and ciliary trafficking[2][3]. ATP6V0D1 is ubiquitously expressed, and its efficient coupling of ATP hydrolysis to proton movement distinguishes it from other d subunit isoforms. Dysfunction of V-ATPase, including ATP6V0D1, is implicated in cancer, neurodegeneration, and skeletal disease, with broad but non-specific small-molecule inhibitors like bafilomycin A1 known to target the complex but not individual subunits[3].

Other names
V-ATPase subunit d1V-type proton ATPase subunit d 1ATP6DP39ATP6DVVATXVPATPDVMA632 kDa accessory protein40 kDa accessory proteinAC39 subunitVacuolar proton pump subunit d 1H(+)-transporting two-sector ATPase subunit DATPase, H+ transporting, lysosomal 38kDaV0 subunit d1V-ATPase subunit DV-ATPase subunit D1
02

Mechanism of action

Inhibition of proton transport/ATPase activity (e.g., by Bafilomycin A1 blocks acidification required for endolysosomal function and autophagy)

03

Biological functions

Organelle acidificationProtein sortingZymogen activationReceptor-mediated endocytosisSynaptic vesicle proton gradient generationAutophagyVesicular traffickingIron homeostasispH regulation in cells
04

Disease associations

Neurodegenerative disease (due to impact on lysosomal function)Cancer (abnormal acidification linked to tumor microenvironment and invasiveness)Bone disease (osteoclast function, bone resorption)Other lysosomal storage diseases
05

Safety considerations

Essential for basic cell physiology; inhibition can cause toxicity in normal tissuesSystemic V-ATPase inhibition is poorly tolerated; tissue or isoform selectivity remains a therapeutic challenge
06

Interacting drugs

Bafilomycin A1 (broad V-ATPase inhibitor)

1 more in the full profile.

Beyond the preview

Go deeper on V-type proton ATPase subunit d1 (ATP6V0D1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-type proton ATPase subunit d1 (ATP6V0D1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call